Wanbury Ltd
Wanbury Q2 FY26: Revenue ₹160.06 Cr, PAT ₹15.18 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Wanbury Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
Q2FY26 Revenue from Operations: ₹160.06 Crore - Year-on-year (YoY) change: -1% compared to Q2FY25 revenue of ₹161.19 Crore - Quarter-on-quarter (QoQ) change: -2% from Q1FY26 ₹163.18 Crore - Q2FY26 EBITDA: ₹25.98 crore - YoY change: +20% - EBITDA Margin: 16.23% - YoY margin change: +21% - Q2FY26 Operating Margin (implied via EBITDA margin): 16.23% as above (no separate operating margin given) - Q2FY26 Profit After Tax (PAT): ₹15.18 crore - YoY change: +89% - PAT Margin: 9.48% - YoY margin change: +91% - Explicit Margin Outlook: No direct margin guidance or explicit margin outlook statement is provided in the presentation.
From Wanbury Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q2FY26 Revenue from Operations: ₹160.06 Crore
- Year-on-year (YoY) change: -1% compared to Q2FY25 revenue of ₹161.19 Crore
- Quarter-on-quarter (QoQ) change: -2% from Q1FY26 ₹163.18 Crore
- H1FY26 Revenue from Operations: ₹323.2 Crore
- YoY growth: 10.57% compared to H1FY25 ₹292.3 Crore
- Business vertical highlights:
- API Revenue Q2FY26: ₹135 Crore (QOQ decline of 5%)
- Formulations Revenue Q2FY26: ₹22 Crore (QOQ growth of 22.2%)
- H1FY26 API revenue growth: 8.2% YoY
- H1FY26 Formulations revenue growth: 17.6% YoY
- Management outlook:
- Formulations business is rebuilding with a break-even envisaged in FY26 and scale-up planned in FY27
2 more points from Wanbury Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Wanbury Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY24: ₹48 Cr CAPEX spent on replacements (₹26 Cr), debottlenecking (₹12 Cr), capacity enhancement (₹10 Cr).
- FY25: ₹64 Cr CAPEX spent on replacements (₹12 Cr), debottlenecking (₹14 Cr), capacity addition for new products (₹38 Cr).
- FY26 (Projected): ₹63 Cr CAPEX planned for new clean room facility (₹12 Cr), new production block + 2 clean rooms (₹45 Cr), new storage area (₹6 Cr).
- FY27 (Projected): ₹7 Cr CAPEX planned for repairs & maintenance (₹0.5 Cr), debottlenecking (₹6.5 Cr).
- Reactor capacity: Current cumulative installed 500 KL; future potential at existing sites 600 KL.
2 more points from Wanbury Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wanbury Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Wanbury Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹162 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wanbury Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Gujarat Themis Biosyn Ltd (Q2 FY26)
42.35 crore, up 21.98% year-on-year from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation — and how it ran
- Senores Pharmaceuticals Ltd (Q2 FY26)
Earnings (PAT) growth has been very strong recently (e.g., 131% Y-o-Y growth in Q2) with sustained profitability momentum. Key concall takeaways from Senores…
- Caplin Point Laboratories Ltd (Q2 FY26)
After 2 years, operating margins could improve to around 40%, if markets remain favorable. Key concall takeaways from Caplin Point Laboratories Ltd's Q2 FY26…
- Indoco Remedies Ltd (Q2 FY26)
R&D spend will reduce from ~5% to ~4% of sales, focusing on vertically integrated, higher efficiency products. Key concall takeaways from Indoco Remedies Ltd's…
Arthneeti Pro · Annual
Wanbury Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wanbury Ltd Q2 FY26 results?
Q2FY26 Revenue from Operations: ₹160.06 Crore - Year-on-year (YoY) change: -1% compared to Q2FY25 revenue of ₹161.19 Crore - Quarter-on-quarter (QoQ) change: -2% from Q1FY26 ₹163.18 Crore - Q2FY26 EBITDA: ₹25.98 crore - YoY change: +20% - EBITDA Margin: 16.23% - YoY margin change: +21% - Q2FY26 Operating Margin (implied via EBITDA margin): 16.23% as above (no separate operating margin given) - Q2FY26 Profit After Tax (PAT): ₹15.18 crore - YoY change: +89% - PAT Margin: 9.48% - YoY margin change: +91% - Explicit Margin Outlook: No direct margin guidance or explicit margin outlook statement is provided in the presentation.
What is Wanbury Ltd share price analysis?
Wanbury Ltd currently shows a neutral. The stock trades at a P/E of 11.3 with a market cap of ₹673 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wanbury Ltd planning capital expenditure?
FY24: ₹48 Cr CAPEX spent on replacements (₹26 Cr), debottlenecking (₹12 Cr), capacity enhancement (₹10 Cr).
Keep Wanbury Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.